Cizzle Biotechnology's £0.62 Million Fundraising and Strategic Developments

NewsCompany Milestones
Written By Cizzle Bio, Inc.

Significant Financial Boost and Joint Broker Appointment

Cizzle Biotechnology Holdings plc has successfully raised £0.62 million through a conditional placing of new ordinary shares. This fundraising will support the development and commercialization of the CIZ1B biomarker test for early-stage lung cancer. Additionally, Cizzle has appointed Allenby Capital as joint broker to the company.

Key Highlights:

  • Raised £0.62 million via a placing of 31,050,000 new shares.

  • Funds will support the development of the CIZ1B test and protect IP.

  • Allenby Capital appointed as joint broker.

For more details, read the full announcement on Cizzle Biotechnology’s website.

Cizzle Bio, Inc.

Cizzle Bio, Inc. is a pioneering biotechnology company focused on developing innovative solutions for early lung cancer detection. With a commitment to advancing cancer diagnostics, Cizzle Bio, Inc. collaborates with leading research institutions and healthcare professionals to bring groundbreaking biomarker blood tests to market, aiming to improve patient outcomes and save lives.

https://www.cizzlebio.com
Previous

Cizzle Biotechnology Holdings plc Annual Report and Financial Statements 2023 Summary
Next

ProteoGenix and Cizzle Biotechnology Collaboration Advances Early Lung Cancer Detection